DDReg pharma

Quailty Driven by Passion

Submit Query

Pharmacovigilance

Home » Blogs » Pharmacovigilance » Page 2
Roadblocks in Global Pharmacovigilance Harmonization

Overcoming Roadblocks in Global Pharmacovigilance Harmonization

All Category, Blogs, Pharmacovigilance /

Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as “the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem”. Global Pharmacovigilance Harmonization, on the other hand, refers to the process of aligning regulations, practices, and standards across countries and regions in order to […]

Overcoming Roadblocks in Global Pharmacovigilance Harmonization Read More »

pharmacovigilance approach for biosimilars market

Pharmacovigilance Approaches for Biosimilars Market Success 

All Category, Blogs, Pharmacovigilance /

The pharmaceutical field has witnessed a tremendous growth of innovation and success in the past few years. Among these advancements, biosimilars have become essential for improving patient access and reducing the cost of therapies. The complexities that even a slight manufacturing differences can lead to variations in protein structure, post-translational modifications, and glycosylation patterns. Since

Pharmacovigilance Approaches for Biosimilars Market Success  Read More »

Current Trends patient engagement in healthcare

Patient Engagement in Healthcare: Current Trends and Future Opportunities

All Category, Blogs, Medical Writing, Pharmacovigilance /

For years, the focus of healthcare development and delivery has been on treatment and outcomes, often with limited input from patients. However, there is now a growing recognition that patients should not just be passive recipients of care—they should be active participants in their own healthcare journey. This patient-centered approach is transforming the way drugs

Patient Engagement in Healthcare: Current Trends and Future Opportunities Read More »

personalized drug in development

Navigating the Challenges of Personalized Medicine in Development

All Category, Blogs, Pharmacovigilance /

The landscape of modern medicine is undergoing a revolutionary transformation, with personalized medicine at the forefront. As we move away from the “one-size-fits-all” approach and embrace treatments tailored to individual genetic profiles, lifestyle, and environmental factors, the potential to improve patient outcomes has never been greater. However, this evolution also comes with unique challenges, particularly

Navigating the Challenges of Personalized Medicine in Development Read More »

Role of Real-World Evidence in Post-Marketing Safety

Leveraging Real-World Evidence to Enhance Post-Marketing Safety Globally

All Category, Blogs, Pharmacovigilance /

Real-World Evidence (RWE) refers to clinical evidence regarding the usage and potential benefits or risks of a medical product, derived from the analysis of Real-World Data (RWD). RWD encompasses information collected from various sources, including electronic health records (EHRs), insurance claims, patient registries, and data from mobile health applications. This evidence is crucial in understanding

Leveraging Real-World Evidence to Enhance Post-Marketing Safety Globally Read More »

Concept of Patient-Centric Pharmacovigilance

How Pharmacovigilance is incorporating the concept of Patient Centricity – An Industry-Leading Approach

All Category, Blogs, Pharmacovigilance /

In healthcare, assuring the safety of medications is equally as vital to developing innovative new treatments. Pharmacovigilance (PV), or “drug safety surveillance”, is the science of detecting, assessing, and preventing adverse drug effects or any related problems from drugs that has traditionally focused on data from healthcare providers, clinical trials and regulatory agencies. Development of

How Pharmacovigilance is incorporating the concept of Patient Centricity – An Industry-Leading Approach Read More »

Pharmacovigilance Strategies for Rare Disease Drugs

Advanced Pharmacovigilance Strategies for Rare Disease Drugs

All Category, Blogs, Pharmacovigilance /

Rare diseases (also referred to as orphan diseases) are diseases that affect less than 5 in 10,000 people in Europe or fewer than 200,000 people in the United States. Although each rare condition affects only a small population, it collectively affects more than 350 million people worldwide and can severely affect a patient’s quality of

Advanced Pharmacovigilance Strategies for Rare Disease Drugs Read More »

Risk Evaluation and Mitigation Strategies for US Drug Development

Risk Evaluation and Mitigation Strategies (REMS) for US Drug Development

All Category, Blogs, Pharmacovigilance /

Risk Evaluation and Mitigation Strategies (REMS) is a drug safety program required by the US FDA for certain medicines that are associated with safety concerns. They typically accompany applications to the US FDA, like New Drug Applications, Biologics License Applications, or Abbreviated New Drug Applications (ANDA), that describe drug safety and ensure that the drug’s

Risk Evaluation and Mitigation Strategies (REMS) for US Drug Development Read More »

Pharmacovigilance in Mexico

Exploring Pharmacovigilance Processes in Mexico

All Category, Blogs, Pharmacovigilance /

The healthcare landscape of Latin America is evolving with pharmacovigilance taking the spotlight to ensure patient safety and regulatory compliance. While there are many contenders of this region, Mexico standards out as a key player with its proactive approach to adverse event monitoring and international alignment that is shaping the future of drug safety in

Exploring Pharmacovigilance Processes in Mexico Read More »

Role of AI in Literature Monitoring in Pharmacovigilance

Harnessing AI for Enhanced Literature Monitoring in Pharmacovigilance

All Category, Blogs, Medical Writing, Pharmacovigilance /

In the rapidly evolving landscape of pharmaceutical safety, integrating Artificial Intelligence (AI) into literature monitoring in pharmacovigilance processes has become necessary. It involves ongoing monitoring and assessment of adverse drug reactions (ADRs), and other potential risks associated with medicinal products. A critical aspect of PV is literature monitoring, which entails reviewing scientific literature, case reports, and

Harnessing AI for Enhanced Literature Monitoring in Pharmacovigilance Read More »